The global inquiry into whether central nervous system stimulants can treat psychiatric conditions beyond their primary indications highlights an ongoing clinical discussion. Ritalin, a brand-name formulation of the central nervous system stimulant methylphenidate, is primarily prescribed to manage attention deficit hyperactivity disorder and narcolepsy. Because methylphenidate modifies neurotransmitter activity by blocking dopamine and norepinephrine transporters, […]